Evidence level: B
中医体质问卷(CCMQ)和多基因风险评分(PRS)各测各的信号:一个用 60 道症状题描述”现在的水位”,一个用几十万个位点描述”天生的大坝”。预测干预应答时它们是互补还是冗余,取决于联合模型的 ΔAUC/ΔNRI 是否显著大于单独模型——这是”辨体论治”能否在精准预防时代立足的测量学裁决。
正文
上一篇文章(#684)裁决了体质 PRS 效应修饰的”绝对-相对分叉”:干预的相对获益跨遗传基线平坦,绝对获益却随 PRS 单调增大。但”效应修饰存在”和”体质分型有增量价值”是两件事。本篇把裁决对象换成预测力本身:在同一个干预 RCT 里,CCMQ 体质评分与 PRS 各自预测应答的独立增量是多少?两者放进同一模型后是互补还是冗余? 这直接决定”辨体”是不是”辨基因”的廉价重复。
先看 PRS 一方的底牌:它确实能预测,但幅度小得让人清醒。 美国糖尿病学会牵头的 Trans-NIH 减重应答遗传学联盟,把七个生活方式干预试验(NUGENOB、DiOGenes、Look AHEAD、糖尿病预防项目 DPP、芬兰糖尿病预防研究 DPS、DIETFITS、PREDIMED-Plus)的个体数据合并,检验 59 个中心性肥胖位点多基因评分的预测力:每升高 1 个标准差,1 年腰围(BMI 校正)少减 0.007(SE=0.003,P=0.03),折合平均减重场景下只有 0.20–0.28 厘米(PMID 35043141)。结论直言”效应小到不具备临床显著性”。另一项 DPP+Look AHEAD 双 RCT 分析检验 91 个肥胖位点:绝大多数位点与 4 年减重、反弹无关联,唯一显著的 MTIF3 rs1885988 交互 P=4.3×10⁻³ 也过不了研究级多重检验(Bonferroni 阈值 P<5.8×10⁻⁴)(PMID 26253612)。遗传负荷对干预应答的预测力存在,但单看 PRS,它只解释应答方差的一小块。
再看 CCMQ 一方的底牌:它能测到 PRS 测不到的东西,但多为横断面关联。 体质问卷的 60 个条目本质上是对”当前表型状态”的压缩编码。台湾生物库 1 万人的横断面研究发现,CM-CQ 44 个条目与自报慢性病的关联大多”每一条都弱、整体有趋势”,其中高血压、痛风、糖尿病等常见病条目显示出超过 2 倍的风险趋势(PMID 40592171)。痰湿质人群则从基因组层面就与代谢病绑定:转录组研究在痰湿质中找出 4 个上调基因(COPS8、GNPDA1、CD52、ARPC3)与 6 个下调基因(GSPT2、CACNB2、FLJ20584、UXS1、IL21R、TNPO),功能注释指向高脂血症与糖尿病易感性(PMID 23548117);系统综述与 meta 分析汇总 30,435 例,痰湿质患代谢综合征的风险是其他体质的 1.74 倍(OR 1.74,95% CI 1.27–2.38)(DOI 10.1016/j.jtcms.2020.10.004)。注意:这些全是”体质→患病风险”的横断面/回顾证据,几乎没有任何一项做的是”体质→干预应答”的前瞻预测。
这里出现一个必须正视的悖论——辨证的疗效加成在 meta 层面可能并不存在。 2026 年发表的最大规模辨证 meta-流行病学研究纳入 137 项系统评价、2,064 项 RCT、187,503 名参与者,比较”纳入辨证分型”与”未纳入辨证分型”的中药 RCT 疗效:两者治疗效应几乎无差别(二分类结局 ROR 0.93,95% CI 0.86–1.00;连续结局 dSMD −1.44);在循环系统疾病与主观结局亚组中,辨证组甚至效应更小(PMID 41671109)。这篇文献没有否定辨证的价值,但它提醒我们:“辨证能指导个体化治疗”这个信念本身需要被测量。当预测对象是”谁受益更多”而非”谁患病风险高”时,体质信息是否还有增量,必须用 ΔAUC/ΔNRI 说话,而不是用历史权威说话。
所以本课题的裁决设计就清晰了。 在一个设计良好的干预 RCT(体质分型指导处方 vs 标准化处方,如 #683 所述)内同时采集 CCMQ 与基因分型:先建”仅 PRS”模型、再建”仅 CCMQ”模型、最后建”PRS+CCMQ”联合模型,逐一比较 ΔAUC/ΔNRI/ΔIDI。三种结局各做一遍——体质评分复评改善、代谢终点改善、依从性保持。判读规则预先写死:联合模型相对最优单模型 ΔAUC≥0.01 且重分类净改善显著 → 互补(两者各测各的信号);ΔAUC 持平、NRI 不显著 → 冗余(体质是遗传负荷的表型代理);若 CCMQ 单独就追平甚至超过 PRS+CCMQ,则提示体质问卷可能已经内嵌了”遗传×环境”的整合表型,此时辨体反而是更经济的预测工具——因为 60 道题的成本远低于基因芯片。
这道裁决的科学意义在于给”辨体”一个可证伪的落点。 传统上,辨体论治的价值靠理论自洽背书;在精准预防时代,它必须能回答”相比直接测基因,你多告诉我多少”。若 CCMQ 与 PRS 冗余,则中医体质学应转向”便宜替代品”定位——用问卷替代芯片做大规模初筛;若互补,则体质测量就解锁了 PRS 捕捉不到的通道(表观遗传、菌群、生活方式印记),获得不可替代的独立预测价值。无论哪种结果,中医体质学都会从”信仰”走进”测量”,这正是本研究池子反复强调的第一性原理:把易学概念翻译成可检验的统计量,让证据而非权威决定去留。
证据与局限
已验证: PRS 能预测生活方式干预应答,但幅度小(Trans-NIH 七试验,1 SD 对应腰围少减 0.20–0.28 cm,PMID 35043141);DPP+Look AHEAD 中 91 个肥胖位点绝大多数无预测力(PMID 26253612);CM-CQ 与慢性病横断面关联存在但单条目弱(PMID 40592171);痰湿质有基因组与 meta 级代谢综合征关联(PMID 23548117;OR 1.74)。
部分验证: 辨证纳入与否在 2,064 项 RCT 的 meta-流行病学比较中疗效无显著差异(ROR 0.93,PMID 41671109)——但这比较的是”RCT 是否用辨证”,不等于”个体水平辨证预测应答无效”,不能过度外推。
待验证: ①同一 RCT 内 CCMQ 与 PRS 的联合模型 ΔAUC/ΔNRI 是否显著;②体质评分改善与代谢终点改善作为预测目标的增量是否一致;③体质分型是否能捕获 PRS 测不到的”遗传×环境”整合信号;④CCMQ 作为 PRS 的”便宜替代”在大规模初筛中的成本-效果。
相关阅读
- 相对获益人人平等,绝对获益偏爱高遗传?——体质 PRS 效应修饰的绝对-相对分叉裁决
- 体质遗传基线越高,干预获益越大还是越小?——体质 PRS 效应修饰检验
- 高/低 PRS 分层的生活方式干预 RCT:遗传负荷高者应答是否衰减
- 研究池子:生物频率密码
证据等级: B(CCMQ 与 PRS 各自预测力有 PubMed 直接支撑;”两者联合增量”属待检验的统计假说)
参考文献: PMID 35043141, PMID 26253612, PMID 40592171, PMID 23548117, PMID 41671109
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Phenotype Questionnaire vs Genetic Score: Who Benefits More? A Head-to-Head Comparison of CCMQ and PRS Predictive Increment
Evidence level: B
The Traditional Chinese Medicine Body Constitution Questionnaire (CCMQ) and Polygenic Risk Scores (PRS) capture distinct signals: one encodes the “current water level” via 60 symptom items, while the other maps the “innate dam” across hundreds of thousands of loci. Whether they are complementary or redundant when predicting intervention response depends on whether the joint model’s ΔAUC/ΔNRI significantly exceeds that of the single models—this is the metrological verdict determining if “distinguishing constitution for treatment” can stand in the era of precision prevention.
Main Text
The previous article (#684) adjudicated the “absolute-relative divergence” of constitution PRS effect modification: relative benefit across genetic baselines is flat, but absolute benefit increases monotonically with PRS. However, “effect modification exists” and “constitution phenotyping adds incremental value” are two distinct matters. This piece shifts the adjudication target to predictive power itself: Within a single intervention RCT, what is the independent incremental predictive value of CCMQ constitution scores versus PRS? Do they become complementary or redundant when placed in the same model? This directly determines whether “distinguishing constitution” is merely a cheap repetition of “distinguishing genes.”
First, look at PRS’s bottom card: It can predict, but the magnitude is soberingly small. The Trans-NIH Genetics of Lifestyle Intervention Response consortium, led by the American Diabetes Association, pooled individual data from seven lifestyle intervention trials (NUGENOB, DiOGenes, Look AHEAD, Diabetes Prevention Program DPP, Finnish Diabetes Prevention Study DPS, DIETFITS, PREDIMED-Plus) to test the predictive power of 59 central obesity loci-based PRS: for every one standard deviation increase, waist circumference (BMI-corrected) decreased by less by 0.007 (SE=0.003, P=0.03), translating to only 0.20–0.28 cm under average weight loss scenarios (PMID 35043141). The conclusion explicitly states “the effect is too small to be clinically significant.” Another analysis of DPP+Look AHEAD double RCTs tested 91 obesity loci: the vast majority showed no association with 4-year weight loss or rebound, and the only significant interaction MTIF3 rs1885988 (P=4.3×10⁻³) failed to pass study-level multiple testing correction (Bonferroni threshold P<5.8×10⁻⁴) (PMID 26253612). Genetic load has predictive power for intervention response, but looking at PRS alone, it explains only a small fraction of the response variance.
Now look at CCMQ’s bottom card: It can measure what PRS cannot, but mostly through cross-sectional associations. The 60 items of the constitution questionnaire are essentially compressed encodings of “current phenotypic states.” A cross-sectional study of 10,000 individuals in the Taiwan BioBank found that associations between CCMQ’s 44 items and self-reported chronic diseases were mostly “weak individually but showed an overall trend,” with common conditions like hypertension, gout, and diabetes showing risk trends exceeding 2-fold (PMID 40592171). Phlegm-Damp constitution individuals are genetically bound to metabolic disorders at the genomic level: transcriptomic studies identified 4 upregulated genes (COPS8, GNPDA1, CD52, ARPC3) and 6 downregulated genes (GSPT2, CACNB2, FLJ20584, UXS1, IL21R, TNPO) in Phlegm-Damp constitution, with functional annotation pointing to hyperlipidemia and diabetes susceptibility (PMID 23548117); a systematic review and meta-analysis pooled 30,435 cases, finding Phlegm-Damp constitution individuals had a 1.74 times higher risk of metabolic syndrome compared to other constitutions (OR 1.74, 95% CI 1.27–2.38) (DOI 10.1016/j.jtcms.2020.10.004). Note: These are all cross-sectional/retrospective evidences of “constitution → disease risk,” with almost none demonstrating prospective prediction of “constitution → intervention response.”
Here arises a paradox that must be confronted—the efficacy bonus of differentiation may not exist at the meta-analytic level. The largest-scale syndrome-differentiation meta-epidemiological study published in 2026 included 137 systematic reviews, 2,064 RCTs, and 187,503 participants, comparing the efficacy of TCM RCTs “including syndrome differentiation” versus “excluding syndrome differentiation”: treatment effects were virtually identical between groups (binary outcomes ROR 0.93, 95% CI 0.86–1.00; continuous outcomes dSMD −1.44); in subgroups of cardiovascular diseases and subjective outcomes, the differentiation group even showed smaller effects (PMID 41671109). This literature does not negate the value of differentiation, but it reminds us: The belief that “differentiation guides individualized treatment” itself requires measurement. When the prediction target is “who benefits more” rather than “who has higher disease risk,” one must speak in terms of ΔAUC/ΔNRI, not historical authority.
Thus, the adjudication design for this topic is clear. Within a well-designed intervention RCT (constitution-guided prescription vs. standardized prescription, as described in #683), collect both CCMQ and genotyping simultaneously: first build a “PRS-only” model, then a “CCMQ-only” model, and finally a “PRS+CCMQ” joint model, comparing ΔAUC/ΔNRI/ΔIDI one by one. Perform this once for each of three outcomes—constitution score re-assessment improvement, metabolic endpoint improvement, and adherence maintenance. Pre-set interpretation rules: if the joint model’s relative ΔAUC ≥ 0.01 compared to the optimal single model and net reclassification improvement is significant → Complementary (each measures distinct signals); if ΔAUC is flat and NRI is not significant → Redundant (constitution acts as a phenotypic proxy for genetic load); if CCMQ alone matches or exceeds PRS+CCMQ, it suggests the questionnaire may already embed an integrated “genetics × environment” phenotype, making constitution differentiation a more economical predictor—since the cost of 60 questions is far lower than genotyping arrays.
The scientific significance of this adjudication lies in providing a falsifiable landing point for “differentiation constitution.” Traditionally, the value of differentiation constitution is backed by theoretical consistency; in the era of precision prevention, it must answer “how much more do you tell me compared to directly measuring genes.” If CCMQ and PRS are redundant, TCM constitution studies should shift to a “cheap alternative” positioning—using questionnaires instead of chips for large-scale initial screening; if complementary, constitution measurement unlocks channels PRS misses (epigenetic, microbiome, lifestyle imprints), gaining irreplaceable independent predictive value. Regardless of the outcome, TCM constitution studies will move from “faith” to “measurement,” which is the first principle repeatedly emphasized by this research pool: translating Yijing concepts into testable statistics, letting evidence rather than authority determine survival.
Evidence and Limitations
Verified: PRS predicts lifestyle intervention response but with small magnitude (Trans-NIH seven trials, 1 SD corresponds to 0.20–0.28 cm less waist loss, PMID 35043141); in DPP+Look AHEAD, 91 obesity loci showed no predictive power for the vast majority (PMID 26253612); CCMQ shows cross-sectional associations with chronic diseases but individual items are weak (PMID 40592171); Phlegm-Damp constitution shows genomic and meta-level associations with metabolic syndrome (PMID 23548117; OR 1.74).
Partially Verified: Inclusion of differentiation showed no significant efficacy difference in meta-epidemiological comparison across 2,064 RCTs (ROR 0.93, PMID 41671109)—but this compares “whether RCTs used differentiation,” not “ineffectiveness of individual-level differentiation prediction,” so over-extrapolation should be avoided.
To Be Verified: ① Whether joint model ΔAUC/ΔNRI within the same RCT is significant for CCMQ vs. PRS; ② Whether incremental value of constitution score improvement and metabolic endpoint improvement as prediction targets is consistent; ③ Whether constitution phenotyping can capture “genetics × environment” integrated signals missed by PRS; ④ Cost-effectiveness of CCMQ as a “cheap alternative” to PRS for large-scale initial screening.
Related Reading
- Relative Benefit Is Equal for All, Absolute Benefit Favors High Genetics? — Adjudication on Absolute-Relative Divergence of Constitution PRS Effect Modification
- Higher Genetic Baseline for Constitution: Does Intervention Benefit Increase or Decrease? — Test of Constitution PRS Effect Modification
- High/Low PRS Stratified Lifestyle Intervention RCT: Does Response Attenuate in High Genetic Load
- Research Pool: Biomolecular Frequency Code
Evidence Level: B (CCMQ and PRS individual predictive powers have direct PubMed support; “joint incremental value” belongs to a statistical hypothesis awaiting verification)
References: PMID 35043141, PMID 26253612, PMID 40592171, PMID 23548117, PMID 41671109
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply